Updates in TROP2-Directed and Other Novel ADCs in Breast Cancer
Dato-DXd Plus Durvalumab Elicits Durable Responses in Metastatic TNBC Regardless of PD-L1 Status
November 22nd 2023Peter Schmid, FRCP, MD, PhD, discusses the evaluation of combination of the datopotamab deruxtecan and durvalumab in patients with first-line triple-negative breast cancer, details safety and efficacy findings derived from the combination in the BEGONIA trial, and highlights ongoing efforts with this combination.
Dr Cortés on Pooled Data for Trastuzumab Deruxtecan in HER2+ Breast Cancer With Brain Metastases
November 21st 2023Javier Cortés, MD, PhD, discusses primary outcomes and safety findings from a pooled analysis of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer who have brain metastases.
Dr Schmid on Key Efficacy Findings With Dato-DXd in Metastatic TNBC
October 25th 2023Peter Schmid, FRCP, MD, PhD, discusses key findings from the phase 1/2 BEGONIA trial in patients with unresectable, metastatic or locally advanced triple-negative breast cancer, highlighting the clinical significance of these findings.
Dato-DXd Provides PFS Benefit in HR+/HER2– Breast Cancer
October 23rd 2023Datopotamab deruxtecan elicited a statistically significant and clinically meaningful improvement in progression-free survival vs chemotherapy for patients with hormone receptor-positive, HER2-low or -negative, metastatic breast cancer.
